Morphine upregulates Toll-like receptor 4 expression and promotes melanomas in mice

References

• Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7(10):797–809.
   PubMed Web of Science ®Google Scholar
• van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–1449.
   PubMed Web of Science ®Google Scholar
• Portenoy RK. Treatment of cancer pain. Lancet. 2011;377(9784):2236–2247.
   PubMed Web of Science ®Google Scholar
• Dalal S, Bruera E. Access to opioid analgesics and pain relief for patients with cancer. Nat Rev Clin Oncol. 2013;10(2):108–116.
   PubMed Web of Science ®Google Scholar
• McCarthy L, Wetzel M, Sliker JK, et al. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001;62(2):111–123.
   PubMed Web of Science ®Google Scholar
• Ghasemi A, Vaseghi G, Hojjatallah A, et al. The effects of morphine on vascular cell adhesion molecule 1(VCAM-1) concentration in lung cancer cells. Arch Physiol Biochem. 2021;127:1–5.
   PubMedGoogle Scholar
• Singleton PA, Lingen MW, Fekete MJ, et al. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 2006;72(1-2):3–11.
   PubMed Web of Science ®Google Scholar
• Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res. 2006;13(3):171–180.
   PubMed Web of Science ®Google Scholar
• Mahbuba W, Lambert DG. Opioids and neovascularization; pro or anti? Br J Anaesth. 2015;115(6):821–824.
   PubMed Web of Science ®Google Scholar
• Vaseghi G, Dana N, Ghasemi A, et al. Morphine promotes migration and lung metastasis of mouse melanoma cells. Braz J Anesthesiol. 2022 [Feb 1]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S010400142200001X
   PubMedGoogle Scholar
• Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and epithelial mesenchymal transition (EMT) in human lung cancer. PLoS One. 2014;9(3):e91577.
   PubMed Web of Science ®Google Scholar
• Zare N, Pourhadi M, Vaseghi G, et al. The potential interplay between opioid and the toll-like receptor 4 (TLR-4). Immunopharmacol Immunotoxicol. 2022 [Sep 16]; 1–13. Available from 10.1080/08923973.2022.2122500
   PubMed Web of Science ®Google Scholar
• Nadeem A, Siddiqui N, Al-Harbi NO, et al. TLR-7 agonist attenuates airway reactivity and inflammation through Nrf2-mediated antioxidant protection in a murine model of allergic asthma. Int J Biochem Cell Biol. 2016;73:53–62.
   PubMed Web of Science ®Google Scholar
• Haghjooy-Javanmard S, Ghasemi A, Laher I, et al. Influence of morphine on TLR4/NF-kB signaling pathway of MCF-7 cells. Bratisl Lek Listy. 2018;119(4):229–233.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Wang JH, Redmond HP. Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol. 2013;20(S3):389–396.
   Google Scholar
• He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44(11):2850–2859.
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008;28(1):20–29.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
   PubMed Web of Science ®Google Scholar
• Ahmad SF, Ansari MA, Nadeem A, et al. Resveratrol improves neuroimmune dysregulation through the inhibition of neuronal Toll-Like receptors and COX-2 signaling in BTBR T + Itpr3tf/J mice. Neuromolecular Med. 2018;20(1):133–146.
   PubMed Web of Science ®Google Scholar
• Ben-Eliyahu S, Page GG, Yirmiya R, et al. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer. 1999;80(6):880–888.
   PubMed Web of Science ®Google Scholar
• Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 2002;62(15):4491–4498.
   PubMed Web of Science ®Google Scholar
• Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer. 2007;97(11):1523–1531.
   PubMed Web of Science ®Google Scholar
• Dana N, Vaseghi G, Haghjooy Javanmard S. Activation of PPARγ inhibits TLR4 signal transduction pathway in melanoma cancer in vitro. Adv Pharm Bull. 2020;10(3):458–463.
   PubMed Web of Science ®Google Scholar
• Dana N, Vaseghi G, Haghjooy Javanmard S. PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling. J Pharm Pharm Sci. 2019;22(1):418–423.
   PubMedGoogle Scholar
• Dana N, Haghjooy Javanmard S, Vaseghi G. The effect of fenofibrate, a PPARα activator on toll-like receptor-4 signal transduction in melanoma both in vitro and in vivo. Clin Transl Oncol. 2020;22(4):486–494.
   PubMed Web of Science ®Google Scholar
• Tegeder I, Grösch S, Schmidtko A, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 2003;63(8):1846–1852.
   PubMed Web of Science ®Google Scholar
• Gach K, Wyrębska A, Fichna J, et al. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol. 2011;384(3):221–230.
   PubMed Web of Science ®Google Scholar
• Koodie L, Yuan H, Pumper JA, et al. Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol. 2014;184(4):1073–1084.
   PubMed Web of Science ®Google Scholar
• Sasamura T, Nakamura S, Iida Y, et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 2002;441(3):185–191.
   PubMed Web of Science ®Google Scholar
• Harimaya Y, Koizumi K, Andoh T, et al. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187(1-2):121–127.
   PubMed Web of Science ®Google Scholar
• Lewis JW, Shavit Y, Terman GW, et al. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides. 1983;4(5):635–638.
   PubMed Web of Science ®Google Scholar
• Huang AS, Moura ER, Leal PC, et al. Evaluation of morphine effect on tumor growth in mice. Clin Exp Pharmacol. 2018;8(3):1–5.
   Google Scholar
• Cao L-H, Li H-T, Lin W-Q, et al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep. 2016;6(1):18706.
   PubMedGoogle Scholar
• Zhang X, Liang Y, Yan Y, et al. Morphine: double-faced roles in the regulation of tumor development. Clin Transl Oncol. 2018;20(7):808–814.
   PubMed Web of Science ®Google Scholar
• Zhang P, Yang M, Chen C, et al. Toll-like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility. Front Immunol. 2020;11:1455.
   PubMed Web of Science ®Google Scholar
• Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011;63(3):772–810.
   PubMed Web of Science ®Google Scholar
• Dana N, Javanmard SH, Vaseghi G. Effect of lipopolysaccharide on toll-like receptor-4 signals in mouse cancer cells. BLL. 2018;118(10):598–601.
   Web of Science ®Google Scholar
• Zhang X, Peng Y, Grace PM, et al. Stereochemistry and innate immune recognition: (+)‐norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll‐like receptor 4 signaling. FASEB J. 2019;33(8):9577–9587.
   PubMed Web of Science ®Google Scholar
• Merighi S, Gessi S, Varani K, et al. Morphine mediates a proinflammatory phenotype via μ-opioid receptor–PKCɛ–akt–ERK1/2 signaling pathway in activated microglial cells. Biochem Pharmacol. 2013;86(4):487–496.
   PubMed Web of Science ®Google Scholar
• Gessi S, Borea PA, Bencivenni S, et al. The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia. FEBS Lett. 2016;590(17):2813–2826.
   PubMed Web of Science ®Google Scholar
• Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24(1):21–44.
   PubMed Web of Science ®Google Scholar
• Huang R-L, Yuan Y, Zou G-M, et al. LPS-stimulated inflammatory environment inhibits BMP-2-induced osteoblastic differentiation through crosstalk between TLR4/MyD88/NF-κB and BMP/smad signaling. Stem Cells Dev. 2014;23(3):277–289.
   PubMed Web of Science ®Google Scholar
• Angrini M, Varthaman A, Cremer I. Toll-like receptors (TLRs) in the tumor microenvironment (TME): a dragon-like weapon in a non-fantasy game of thrones. Adv Exp Med Biol. 2020;1263:145–173.
   PubMed Web of Science ®Google Scholar
• Pradere J-P, Dapito DH, Schwabe RF. The yin and yang of toll-like receptors in cancer. Oncogene. 2014;33(27):3485–3495.
   PubMed Web of Science ®Google Scholar
• Messaritakis I, Stogiannitsi M, Koulouridi A, et al. Evaluation of the detection of toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS One. 2018;13(6):e0197327.
   PubMed Web of Science ®Google Scholar
• Sootichote R, Thuwajit P, Singsuksawat E, et al. Compound a attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8. BMC Cancer. 2018;18(1):231.
   PubMedGoogle Scholar
• Huy H, Kim T-D, Kim WS, et al. TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells. Biochem Biophys Res Commun. 2018;506(1):33–40.
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu C, Ma J, et al. Toll-like receptor 4 promotes angiogenesis in pancreatic cancer via PI3K/AKT signaling. Exp Cell Res. 2016;347(2):274–282.
   PubMed Web of Science ®Google Scholar
• Huhta H, Helminen O, Lehenkari PP, et al. Toll-like receptors 1, 2, 4 and 6 in esophageal epithelium, Barrett’s esophagus, dysplasia and adenocarcinoma. Oncotarget. 2016;7(17):23658–23667.
   PubMedGoogle Scholar
• Kohtz PD, Halpern AL, Eldeiry MA, et al. Toll-like receptor-4 is a mediator of proliferation in esophageal adenocarcinoma. Ann Thorac Surg. 2019;107(1):233–241.
   PubMed Web of Science ®Google Scholar
• Park GB, Chung YH, Kim D. Induction of galectin-1 by TLR-dependent PI3K activation enhances epithelial-mesenchymal transition of metastatic ovarian cancer cells. Oncol Rep. 2017;37(5):3137–3145.
   PubMed Web of Science ®Google Scholar
• Wang K, Wang J, Wei F, et al. Expression of TLR4 in non-small cell lung cancer is associated with PD-L1 and poor prognosis in patients receiving pulmonectomy. Front Immunol. 2017;8:456.
   PubMed Web of Science ®Google Scholar
• Ahmad SF, Zoheir KMA, Ansari MA, et al. Histamine 4 receptor promotes expression of costimulatory B7.1/B7.2 molecules, CD28 signaling and cytokine production in stress-induced immune responses. J Neuroimmunol. 2015;289:30–42.
   PubMed Web of Science ®Google Scholar
• McCall KD, Muccioli M, Benencia F. Toll-like receptors signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1223:81–97.
   PubMed Web of Science ®Google Scholar
• Grace PM, Ramos KM, Rodgers KM, et al. Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae. Neuroscience. 2014;280:299–317.
   PubMed Web of Science ®Google Scholar
• Yang H, Zhou H, Feng P, et al. Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29:92.
   PubMed Web of Science ®Google Scholar
• Gonçalves M, Cappellari ÁR, Santos Junior A, et al. Effect of LPS on the viability and proliferation of human oral and esophageal cancer cell lines. Braz Arch Biol Technol. 2016;59:1–10.
   Web of Science ®Google Scholar
• Nylund G, Pettersson A, Bengtsson C, et al. Functional expression of mu-opioid receptors in the human Colon cancer cell line, HT-29, and their localization in human Colon. Dig Dis Sci. 2008;53(2):461–466.
   PubMed Web of Science ®Google Scholar
• Saxon JA, Sherrill TP, Polosukhin VV, et al. Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment. Oncoimmunology. 2016;5(6):e1168549.
   PubMed Web of Science ®Google Scholar
• Friedmann-Morvinski D, Narasimamurthy R, Xia Y, et al. Targeting NF-κB in glioblastoma: a therapeutic approach. Sci Adv. 2016;2(1):e1501292.
   PubMed Web of Science ®Google Scholar
• Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604–4613.
   PubMed Web of Science ®Google Scholar
• Kawauchi K, Araki K, Tobiume K, et al. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol. 2008;10(5):611–618.
   PubMed Web of Science ®Google Scholar